[go: up one dir, main page]

DE69728914D1 - Pharmazeutische Zusammensetzung gegen durch Papillomaviren verursachte Tumoren und Infektionen - Google Patents

Pharmazeutische Zusammensetzung gegen durch Papillomaviren verursachte Tumoren und Infektionen

Info

Publication number
DE69728914D1
DE69728914D1 DE69728914T DE69728914T DE69728914D1 DE 69728914 D1 DE69728914 D1 DE 69728914D1 DE 69728914 T DE69728914 T DE 69728914T DE 69728914 T DE69728914 T DE 69728914T DE 69728914 D1 DE69728914 D1 DE 69728914D1
Authority
DE
Germany
Prior art keywords
papillomaviruses
pharmaceutical composition
infections caused
composition against
against tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69728914T
Other languages
English (en)
Other versions
DE69728914T2 (de
Inventor
Jean-Marc Balloul
Nadine Bizouarne
Marie Paule Kieny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9494633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69728914(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene SA filed Critical Transgene SA
Publication of DE69728914D1 publication Critical patent/DE69728914D1/de
Application granted granted Critical
Publication of DE69728914T2 publication Critical patent/DE69728914T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69728914T 1996-07-30 1997-07-29 Pharmazeutische Zusammensetzung gegen durch Papillomaviren verursachte Tumoren und Infektionen Expired - Lifetime DE69728914T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9609584 1996-07-30
FR9609584A FR2751879B1 (fr) 1996-07-30 1996-07-30 Composition pharmaceutique contre les tumeurs et infections a papillomavirus

Publications (2)

Publication Number Publication Date
DE69728914D1 true DE69728914D1 (de) 2004-06-03
DE69728914T2 DE69728914T2 (de) 2005-04-07

Family

ID=9494633

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69728914T Expired - Lifetime DE69728914T2 (de) 1996-07-30 1997-07-29 Pharmazeutische Zusammensetzung gegen durch Papillomaviren verursachte Tumoren und Infektionen
DE69706825T Expired - Lifetime DE69706825T3 (de) 1996-07-30 1997-07-29 Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69706825T Expired - Lifetime DE69706825T3 (de) 1996-07-30 1997-07-29 Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen

Country Status (12)

Country Link
EP (2) EP1149910B1 (de)
JP (2) JP4070815B2 (de)
AT (2) ATE265535T1 (de)
AU (1) AU736720B2 (de)
CA (1) CA2234263C (de)
DE (2) DE69728914T2 (de)
DK (2) DK0862634T4 (de)
ES (2) ES2163795T5 (de)
FR (1) FR2751879B1 (de)
HK (1) HK1043809B (de)
PT (2) PT862634E (de)
WO (1) WO1998004705A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
WO2000000217A1 (fr) * 1998-06-26 2000-01-06 Aventis Pasteur Immunisation a ciblage mucosal
RU2551982C2 (ru) * 2006-06-20 2015-06-10 Трансжене С.А. Способ получения поксвирусов и композиции поксвирусов
NZ593749A (en) 2009-01-20 2012-05-25 Transgene Sa Soluble icam-1 as biomarker for prediction of therapeutic response
DK2411815T3 (en) 2009-03-24 2015-11-30 Transgene Sa Biomarker MONITORING OF PATIENTS
SI2419728T1 (sl) 2009-04-17 2014-03-31 Transgene Sa Bio-označevalec za monitoring pacientov
JP2012526532A (ja) 2009-05-12 2012-11-01 トランジェーヌ、ソシエテ、アノニム 不死化鳥類細胞系およびその用途
WO2011003905A1 (en) 2009-07-10 2011-01-13 Transgene Sa Biomarker for selecting patients and related methods
SG178090A1 (en) 2009-07-21 2012-03-29 Transgene Sa Enzymatic composition for the digestion of chicken embryos
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
KR102507483B1 (ko) 2014-12-01 2023-03-07 트랜스진 안정한 액체 백시니아 바이러스 제제
FR3042121A1 (fr) * 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
EP3624851A1 (de) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stabile virushaltige zusammensetzung
EP3624845A1 (de) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stabile virushaltige zusammensetzung
AU2019336940A1 (en) 2018-09-06 2021-03-11 Bavarian Nordic A/S Storage improved poxvirus compositions
CA3170701A1 (en) 2020-03-12 2021-09-16 Bavarian Norcig A/S Compositions improving poxvirus stability

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643817B1 (fr) * 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
EP0451550A3 (en) † 1990-03-20 1991-11-06 Behringwerke Aktiengesellschaft Seroreactive epitopes of human papillomavirus (hpv) 16 proteins
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
WO1993002184A1 (en) * 1991-07-19 1993-02-04 The University Of Queensland Papilloma virus vaccine
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide for vaccination against the umbilical cord virus
WO1996011279A2 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique

Also Published As

Publication number Publication date
PT862634E (pt) 2002-03-28
DE69706825T2 (de) 2002-05-02
EP1149910B1 (de) 2004-04-28
ATE265535T1 (de) 2004-05-15
FR2751879B1 (fr) 1998-10-30
CA2234263C (fr) 2009-10-13
AU3855297A (en) 1998-02-20
JP2007254474A (ja) 2007-10-04
ES2215805T3 (es) 2004-10-16
WO1998004705A1 (fr) 1998-02-05
ES2163795T5 (es) 2006-07-16
EP0862634A1 (de) 1998-09-09
JP2000500662A (ja) 2000-01-25
HK1043809A1 (en) 2002-09-27
DE69728914T2 (de) 2005-04-07
DK0862634T4 (da) 2006-05-08
EP0862634B1 (de) 2001-09-19
PT1149910E (pt) 2004-09-30
JP4070815B2 (ja) 2008-04-02
CA2234263A1 (fr) 1998-02-05
HK1043809B (zh) 2004-12-03
DE69706825T3 (de) 2006-08-24
ES2163795T3 (es) 2002-02-01
FR2751879A1 (fr) 1998-02-06
DE69706825D1 (de) 2001-10-25
EP1149910A1 (de) 2001-10-31
ATE205881T1 (de) 2001-10-15
JP4198735B2 (ja) 2008-12-17
EP0862634B2 (de) 2006-03-01
DK0862634T3 (da) 2002-01-21
AU736720B2 (en) 2001-08-02
DK1149910T3 (da) 2004-08-02

Similar Documents

Publication Publication Date Title
DE69728914D1 (de) Pharmazeutische Zusammensetzung gegen durch Papillomaviren verursachte Tumoren und Infektionen
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
TR199801179T2 (xx) Yeni taksoitler, bunlar�n haz�rlanmalar� ve ila� bile�imleri.
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
FI891361A (fi) Menetelmä farmaseuttisesti vaikuttavien aryylihydratsonien valmistamiseksi
DK1077941T3 (da) Forbindelser med væksthormonfrigörende egenskaber
NO971625L (no) Nye peptider med immunomodulatoriske effekter
CS156792A3 (en) Substituted diaminophthalimides and compounds analogous thereto
ATE401896T1 (de) Pharmazeutische zusammensetzungen mit tumor nekrose faktor und 2-methoxyestron-3-o-sulphamat als estrone sulphatasehemmern
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
BR1100143A (pt) Composto, e, composição farmacêutica.
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
CA2111083A1 (en) Novel peptides, their preparation and use
DE60035133D1 (de) Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten
CA2027814A1 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
UA26442C2 (uk) Фармкомпозиція для профілактики і лікуваhhя захворюваhь, пов'язаhих з порушеhhям обміhу речовиh
EA199700032A1 (ru) Дезинфицирующий состав "велтолен"
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
YU46302A (sh) Supstituisani piroli
ZA953584B (en) Novel active peptide and its preparation
TR200100354T2 (tr) NK-2 Antagonist hareketine sahip monosiklik bileşimler ve oluşumlar.
SE9401596D0 (sv) New compounds
NZ505085A (en) Pharmaceutical compositions comprising bipapcitide monocarboxylate and/or bipapcitide dicarboxylate for imaging and treating thrombi

Legal Events

Date Code Title Description
8364 No opposition during term of opposition